Innovation Ltd Panacea Sells 313,446 Shares of Atara Biotherapeutics (NASDAQ:ATRA) Stock

Atara Biotherapeutics, Inc. (NASDAQ:ATRA) major shareholder Innovation Ltd Panacea sold 313,446 shares of the firm’s stock in a transaction that occurred on Thursday, May 7th. The stock was sold at an average price of $10.10, for a total value of $3,165,804.60. Following the completion of the sale, the insider directly owned 1,011,000 shares in the company, valued at approximately $10,211,100. This trade represents a 23.67% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Major shareholders that own at least 10% of a company’s stock are required to disclose their sales and purchases with the SEC.

Atara Biotherapeutics Stock Up 11.7%

Shares of NASDAQ:ATRA opened at $9.81 on Wednesday. The company has a market cap of $83.48 million, a PE ratio of 3.14 and a beta of -0.30. The company’s 50-day moving average price is $5.47 and its 200 day moving average price is $9.18. Atara Biotherapeutics, Inc. has a fifty-two week low of $3.92 and a fifty-two week high of $19.15.

Atara Biotherapeutics (NASDAQ:ATRA) last issued its quarterly earnings data on Tuesday, May 12th. The biotechnology company reported ($0.29) earnings per share for the quarter. The firm had revenue of $0.52 million during the quarter. Atara Biotherapeutics had a net margin of 27.07% and a negative return on equity of 79.12%. As a group, equities analysts anticipate that Atara Biotherapeutics, Inc. will post 0.2 EPS for the current year.

Key Headlines Impacting Atara Biotherapeutics

Here are the key news stories impacting Atara Biotherapeutics this week:

• Positive Sentiment: Atara reported first-quarter 2026 financial results and operational progress, which gives investors fresh visibility into the company’s turnaround efforts and pipeline development. Atara Biotherapeutics Announces First Quarter 2026 Financial Results and Operational Progress
• Neutral Sentiment: The company’s quarterly earnings showed a loss of $0.29 per share on just $0.52 million in revenue, highlighting that Atara remains a small, early-stage biotech with limited sales. Atara Biotherapeutics earnings and stock information
• Negative Sentiment: Pomerantz LLP announced a class action lawsuit against Atara Biotherapeutics and certain officers, adding legal uncertainty and potential costs for the company. Pomerantz class action announcement
• Negative Sentiment: Multiple law firms are urging shareholders to join the securities lawsuit before the May 22 lead-plaintiff deadline, reinforcing the legal pressure on ATRA. Deadline alert for Atara securities lawsuit
• Negative Sentiment: Major shareholder Innovation Ltd Panacea sold 313,446 shares, a large stake reduction that can weigh on sentiment because it may signal reduced confidence or simply add supply to the market. Insider sale by major shareholder Innovation Ltd Panacea

Institutional Trading of Atara Biotherapeutics

Hedge funds and other institutional investors have recently modified their holdings of the company. Globeflex Capital L P raised its stake in shares of Atara Biotherapeutics by 399.6% in the 4th quarter. Globeflex Capital L P now owns 77,224 shares of the biotechnology company’s stock worth $1,397,000 after buying an additional 61,766 shares in the last quarter. Marshall Wace LLP bought a new stake in shares of Atara Biotherapeutics in the 2nd quarter worth $327,000. Renaissance Technologies LLC raised its stake in shares of Atara Biotherapeutics by 58.6% in the 4th quarter. Renaissance Technologies LLC now owns 30,040 shares of the biotechnology company’s stock worth $543,000 after buying an additional 11,104 shares in the last quarter. Bridgeway Capital Management LLC raised its stake in shares of Atara Biotherapeutics by 133.5% in the 4th quarter. Bridgeway Capital Management LLC now owns 32,691 shares of the biotechnology company’s stock worth $591,000 after buying an additional 18,691 shares in the last quarter. Finally, Vanguard Group Inc. raised its holdings in shares of Atara Biotherapeutics by 6.6% in the 3rd quarter. Vanguard Group Inc. now owns 203,438 shares of the biotechnology company’s stock worth $2,915,000 after purchasing an additional 12,677 shares in the last quarter. Institutional investors own 70.90% of the company’s stock.

Wall Street Analysts Forecast Growth

Several analysts have weighed in on the company. Canaccord Genuity Group set a $13.00 target price on Atara Biotherapeutics and gave the company a “buy” rating in a research note on Friday. New Street Research set a $6.00 target price on Atara Biotherapeutics in a research note on Tuesday, January 13th. Weiss Ratings reaffirmed a “sell (d)” rating on shares of Atara Biotherapeutics in a research note on Friday, March 27th. Finally, Wall Street Zen downgraded shares of Atara Biotherapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, March 21st. One research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus target price of $9.50.

About Atara Biotherapeutics

Atara Biotherapeutics, Inc is a biotechnology company focused on the discovery, development and commercialization of novel T-cell immunotherapies to transform the treatment of cancer and autoimmune disease. Headquartered in South San Francisco, California, Atara leverages its proprietary off-the-shelf allogeneic Epstein-Barr virus (EBV)-directed T-cell platform to generate engineered cell therapies designed to target EBV-driven malignancies and immune-mediated disorders.

The company’s lead product candidate, tabelecleucel, is an off-the-shelf, EBV-specific T-cell therapy in clinical development for the treatment of EBV-positive post-transplant lymphoproliferative disease (PTLD) and other EBV-associated cancers.